A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis

Brittany M Edens, Jianhua Yan, Nimrod Miller, Han-Xiang Deng, Teepu Siddique, Yongchao C Ma, Brittany M Edens, Jianhua Yan, Nimrod Miller, Han-Xiang Deng, Teepu Siddique, Yongchao C Ma

Abstract

The etiological underpinnings of amyotrophic lateral sclerosis (ALS) are complex and incompletely understood, although contributions to pathogenesis by regulators of proteolytic pathways have become increasingly apparent. Here, we present a novel variant in UBQLN4 that is associated with ALS and show that its expression compromises motor axon morphogenesis in mouse motor neurons and in zebrafish. We further demonstrate that the ALS-associated UBQLN4 variant impairs proteasomal function, and identify the Wnt signaling pathway effector beta-catenin as a UBQLN4 substrate. Inhibition of beta-catenin function rescues the UBQLN4 variant-induced motor axon phenotypes. These findings provide a strong link between the regulation of axonal morphogenesis and a new ALS-associated gene variant mediated by protein degradation pathways.

Keywords: ALS; UBQLN4; axon morphogenesis; beta-catenin; cell biology; neurodegeneration; neuroscience; ubiquitin proteasome system (UPS); zebrafish.

Conflict of interest statement

The authors declare that no competing interests exist.

Figures

Figure 1.. The UBQLN4 c.269A>C (p.D90A) variant…
Figure 1.. The UBQLN4 c.269A>C (p.D90A) variant identified in a familial ALS case.
(A) Pedigree of a family with ALS. The proband (III3, arrow) had disease onset at 55 years of age, with disease duration of 22 months. Her mother (II3) died of ALS at 62 years of age without clear information regarding disease onset. Her maternal grandfather (I2) died in a traffic accident without any known neurological problems. Her maternal aunt (II2) developed ALS with disease onset at 51 years of age, and disease duration of 36 months. Her cousin (III1) developed ALS at 56 years of age and died five years later. (B) Predicted structural and functional domains of UBQLN4 with an arrow indicating the position of the mutation site. Domains include a UBL: ubiquitin-like domain, aa 13–83; four STI1 heat-shock-chaperonin-binding motifs, aa 192–229, 230–261, 393–440 and 444–476; and a UBA: ubiquitin-associated domain, aa 558–597. (C) Sequencing chromatograms of UBQLN4 wild-type allele in control and mutant allele in the patient with ALS. An adenine to cytosine substitution is present in the ALS patient, resulting in the change from aspartate to alanine at the ninetieth amino acid, D90A. DOI:http://dx.doi.org/10.7554/eLife.25453.003
Figure 2.. Expression of UBQLN4 D90A results…
Figure 2.. Expression of UBQLN4D90A results in motor axon branching abnormalities in vitro and in vivo.
(A) Representative images of primary mouse spinal motor neurons transfected with pCAG-GFP alone, or co-transfected with UBQLN4-WT or UBQLN4D90A. Scale bar: 20 μm. (B) Representative images of lateral whole-mount zebrafish spinal cords from uninjected, UBQLN4-WT mRNA, or UBQLN4D90A mRNA injected embryos. Scale bar: 50 μm. (C) Quantification of total neurites in (A) revealed an increase in neurite number in UBQLN4D90A transfected neurons compared to pCAG-GFP-only and UBQLN4-WT transfected neurons (n = 30 cells per group, p<0.0001). Data are quantified from three independent experiments and are mean ± SEM. ****p<0.0001, one-way ANOVA with Bonferroni post-hoc test. (D) Quantification of percentage of motor axons with aberrant branching in (B) revealed an increase in the percentage of affected motor axons in UBLQN4D90A injected zebrafish compared to both uninjected and UBQLN4-WT injected controls (n = 36 embryos per group, p<0.0001). The difference between uninjected and UBQLN4-WT injected fish was not significant (p=0.155). The average motor axon length was not significantly different among three groups (p=0.2034). Data are from three independent experiments and are mean ± SEM. ****p<0.0001, one-way ANOVA with Bonferroni post-hoc test. DOI:http://dx.doi.org/10.7554/eLife.25453.004
Figure 2—figure supplement 1.. Cultured primary motor…
Figure 2—figure supplement 1.. Cultured primary motor neurons express the motor neuron marker Islet1.
(A) Representative images of primary mouse spinal cord neurons transfected with pCAG-GFP and UBQLN4-WT or UBQLN4D90A, stained with Islet1 (red) and DAPI (blue). Scale bar: 20 μm. DOI:http://dx.doi.org/10.7554/eLife.25453.005
Figure 2—figure supplement 2.. UBQLN4-WT and UBQLN4…
Figure 2—figure supplement 2.. UBQLN4-WT and UBQLN4D90A are expressed at similar levels in primary mouse motor neurons and in zebrafish embryos.
(A) Representative images of primary mouse spinal cord neurons transfected with pCAG-GFP and Flag-tagged UBQLN4-WT or UBQLN4D90A, stained with anti-Flag antibody (red) and DAPI (blue). Scale bar: 20 μm. (B) Western blot of UBQLN4/Flag levels from zebrafish embryos injected with UBQLN4-WT or UBQLN4D90A mRNA, and uninjected controls. Actin Western blot indicates equal protein loading. (C) Quantification of Flag signal in (B) confirmed that UBQLN4-WT and UBQLN4D90A mRNAs are expressed at similar levels (p=0.77). Data are from three independent experiments and are mean ± SEM. ns: p>0.05, two-tailed Student’s t-test. DOI:http://dx.doi.org/10.7554/eLife.25453.006
Figure 3.. Expression of UBQLN4 D90A impairs…
Figure 3.. Expression of UBQLN4D90A impairs proteasomal degradation and results in beta-catenin accumulation.
(A) Representative images of NSC-34 cells transfected with UbG67V-GFP alone, or co-transfected with UBQLN4-WT or UBQLN4D90A. DAPI staining is shown in blue. Scale bar: 100 μm. (B) Quantification of GFP levels in (A) revealed reduced proteasomal turnover following UBQLN4D90A expression. GFP signal, normalized to DAPI, was greater in UBQLN4D90A transfected cells than in UbG67V-GFP-only transfected cells (p=0.0008), or UBQLN4-WT transfected cells (p=0.0088). The difference in GFP level between UbG67V-GFP -only and UBQLN4-WT transfected cells was not significant (p=0.1114). Results are from three independent experiments and are mean ± SEM. ***p<0.001, **p<0.01, one-way ANOVA with Bonferroni post-hoc test. (C) Cycloheximide protein stability assay. GFP protein stability is compared between UbG67V-GFP-only, UbG67V-GFP + UBQLN4-WT, and UbG67V-GFP + UBQLN4D90A transfected NSC-34 cells treated with cycloheximide for 0, 2, 4, and 6 hr. Quantification of GFP level revealed impeded protein turnover in UBQLN4D90A transfected cells. GFP level of UbG67V-GFP + UBQLN4D90A transfected cells was significantly greater than that of UbG67V-GFP + UBQLN4-WT transfected cells at 2, 4, and 6 hr with cycloheximide treatment (p=0.024 (2 hr), p=0.0038 (4 hr), and p=0.036 (6 hr)). GFP level of UbG67V-GFP + UBQLN4D90A transfected cells was significantly greater than that of UbG67V-GFP-only transfected cells (p=0.0068 (2 hr), p=0.0093 (4 hours), and p=0.032 (6 hr)). Results are from three independent experiments and are mean ± SEM. **p<0.01, *p<0.05, one-way ANOVA with Bonferroni post-hoc test. (D) Representative Western blot of the cycloheximide protein stability assay. Actin serves as a loading control. (E) Western blot of beta-catenin levels from UBQLN4-WT, UBQLN4D90A and non-transfected NSC-34 cells. GAPDH Western blot indicates equal protein loading. (F) Quantification of beta-catenin signal in (D) indicated greater beta-catenin levels in UBQLN4D90A transfected and non-transfected cells as compared to UBQLN4-WT transfected cells (p=0.0174 and p=0.0326, respectively). Results are from three independent experiments and are mean ± SEM. *p<0.05, one-way ANOVA with Bonferroni post-hoc test. (G) Representative images of primary mouse neurons transfected with pCAG-GFP and UBQLN4-WT or UBQLN4D90A, stained for beta-catenin. Scale bar: 20 μm. (G) Quantification of beta-catenin localization in (F) revealed increased nuclear localization of beta-catenin in UBQLN4D90A transfected cells as compared to UBQLN4-WT transfected cells (n = 22 or more cells per group, p=0.0038). Data are from three independent experiments and are mean ± SEM. **p<0.01, two-tailed Student’s t-test. DOI:http://dx.doi.org/10.7554/eLife.25453.007
Figure 4.. UBQLN4 D90A -induced phenotypes are…
Figure 4.. UBQLN4D90A-induced phenotypes are rescued by beta-catenin inhibition.
(A) Representative images of primary mouse neurons transfected with pCAG-GFP and UBQLN4-WT or UBQLN4D90A, treated with 0.1 μM quercetin or DMSO. Cells are stained for beta-catenin. Scale bar: 20 μm. (B) Quantification of beta-catenin localization in (A) revealed a rescue effect of quercetin on increased nuclear localization of beta-catenin caused by UBQLN4D90A. UBQLN4D90A transfected cells showed a dramatic increase of nuclear beta-catenin localization compared to UBQLN4-WT transfected cells (n = 25 or more cells per group, p<0.05). The increase was rescued by the application of quercetin (n = 25 or more cells per group, p=0.48). Data are from three independent experiments and are mean ± SEM. *p<0.05, one-way ANOVA with Bonferroni post-hoc test. (C) Representative images of primary mouse spinal cord neurons transfected with pCAG-GFP and UBQLN4-WT or UBQLN4D90A, treated with 0.1 μM quercetin or DMSO. Scale bar: 20 μm. (D) Quantification of total neurite numbers in (C) revealed a rescue effect of quercetin on increased neurite number in UBQLN4D90A transfected cells. The number of neurites present in UBQLN4D90A transfected cells was significantly greater than that in UBQLN4-WT transfected cells (n = 30 cells per group, p<0.0001). Quercetin treatment rescued the increased number of neurites induced by UBQLN4D90A transfection (n = 30 cells per group, p<0.0001). Data are from three independent experiments and are mean ± SEM. ****p<0.0001, one-way ANOVA with Bonferroni post-hoc test. (E) Representative images of lateral whole-mount zebrafish spinal cord from uninjected controls or UBQLN4D90A mRNA injected embryos, treated with DMSO or 50 μM quercetin. Scale bar: 50 μm. (F) Quantification of the percentage of motor axons with aberrant branching in (E) revealed a rescue effect of quercetin on UBQLN4D90A injected embryos. UBQLN4D90A injected embryos showed a significantly greater percentage of affected motor axons compared to uninjected controls (n = 60 embryos per group, p<0.0001). Quercetin treatment rescued aberrant motor axon branching in UBQLN4D90A injected embryos (n = 60 embryos per group, p<0.0001). Data are from three independent experiments and are mean ± SEM. ****p<0.0001, one-way ANOVA with Bonferroni post-hoc test. DOI:http://dx.doi.org/10.7554/eLife.25453.008
Figure 5.. Schematic model illustrating proposed roles…
Figure 5.. Schematic model illustrating proposed roles for wild-type (A) and ALS-associated UBQLN4D90A (B) in motor axon morphogenesis.
(A) Wild-type UBQLN4 associates with beta-catenin through its UBA domain, and with the proteasome through its UBL domain. These interactions allow for the degradation of beta-catenin, which in turn modulates gene expression to control motor axon morphogenesis. (B) The ALS-associated UBQLN4D90A variant is deficient in mediating proteasomal degradation of beta-catenin, leading to its accumulation and excessive induction of gene expression. Hyperactivation of beta-catenin-controlled genes dysregulates axon morphogenesis, causing aberrant axon branching in motor neurons. DOI:http://dx.doi.org/10.7554/eLife.25453.009

References

    1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. The EMBO Journal. 1997;16:3797–3804. doi: 10.1093/emboj/16.13.3797.
    1. Avilés EC, Stoeckli ET. Canonical wnt signaling is required for commissural axon guidance. Developmental Neurobiology. 2016;76:190–208. doi: 10.1002/dneu.22307.
    1. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE. Family-based association between Alzheimer's disease and variants in UBQLN1. New England Journal of Medicine. 2005;352:884–894. doi: 10.1056/NEJMoa042765.
    1. Burguete AS, Almeida S, Gao FB, Kalb R, Akins MR, Bonini NM. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. eLife. 2015;4:e08881. doi: 10.7554/eLife.08881.
    1. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, Dahrouge S, Antel JP. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Developmental Dynamics. 1992;194:209–221. doi: 10.1002/aja.1001940306.
    1. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Developmental Cell. 2008;15:344–357. doi: 10.1016/j.devcel.2008.08.012.
    1. Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Annals of Neurology. 2013;74:180–187. doi: 10.1002/ana.23946.
    1. Clark JA, Southam KA, Blizzard CA, King AE, Dickson TC. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Journal of Chemical Neuroanatomy. 2016;76:35–47. doi: 10.1016/j.jchemneu.2016.03.003.
    1. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nature Biotechnology. 2000;18:538–543. doi: 10.1038/75406.
    1. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211–215. doi: 10.1038/nature10353.
    1. El Ayadi A, Stieren ES, Barral JM, Boehning D. Ubiquilin-1 regulates amyloid precursor protein maturation and degradation by stimulating K63-linked polyubiquitination of lysine 688. PNAS. 2012;109:13416–13421. doi: 10.1073/pnas.1206786109.
    1. Fahed AC, McDonough B, Gouvion CM, Newell KL, Dure LS, Bebin M, Bick AG, Seidman JG, Harter DH, Seidman CE. UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration. Annals of Neurology. 2014;75:793–798. doi: 10.1002/ana.24164.
    1. González-Pérez P, Lu Y, Chian RJ, Sapp PC, Tanzi RE, Bertram L, McKenna-Yasek D, Gao FB, Brown RH. Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not Typical ALS. Neurobiology of Disease. 2012;48:391–398. doi: 10.1016/j.nbd.2012.06.018.
    1. Groen EJ, Gillingwater TH. UBA1: at the Crossroads of Ubiquitin Homeostasis and Neurodegeneration. Trends in Molecular Medicine. 2015;21:622–632. doi: 10.1016/j.molmed.2015.08.003.
    1. Hamilton AM, Zito K. Breaking it down: the ubiquitin proteasome system in neuronal morphogenesis. Neural Plasticity. 2013;2013:196848. doi: 10.1155/2013/196848.
    1. Hjerpe R, Bett JS, Keuss MJ, Solovyova A, McWilliams TG, Johnson C, Sahu I, Varghese J, Wood N, Wightman M, Osborne G, Bates GP, Glickman MH, Trost M, Knebel A, Marchesi F, Kurz T. UBQLN2 mediates autophagy-independent protein aggregate clearance by the proteasome. Cell. 2016;166:935–949. doi: 10.1016/j.cell.2016.07.001.
    1. Huang EJ, Zhang J, Geser F, Trojanowski JQ, Strober JB, Dickson DW, Brown RH, Shapiro BE, Lomen-Hoerth C. Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathology. 2010;20:1069–1076. doi: 10.1111/j.1750-3639.2010.00413.x.
    1. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C, Rouleau GA, Drapeau P. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Human Molecular Genetics. 2010;19:671–683. doi: 10.1093/hmg/ddp534.
    1. Kamboh MI, Minster RL, Feingold E, DeKosky ST. Genetic association of ubiquilin with Alzheimer's disease and related quantitative measures. Molecular Psychiatry. 2006;11:273–279. doi: 10.1038/sj.mp.4001775.
    1. Kim SH, Shi Y, Hanson KA, Williams LM, Sakasai R, Bowler MJ, Tibbetts RS. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. Journal of Biological Chemistry. 2009;284:8083–8092. doi: 10.1074/jbc.M808064200.
    1. Ko HS, Uehara T, Tsuruma K, Nomura Y. Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Letters. 2004;566:110–114. doi: 10.1016/j.febslet.2004.04.031.
    1. Lee DY, Brown EJ. Ubiquilins in the crosstalk among proteolytic pathways. Biological Chemistry. 2012;393:441–447. doi: 10.1515/hsz-2012-0120.
    1. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG, Exome Aggregation Consortium Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291. doi: 10.1038/nature19057.
    1. Lemmens R, Van Hoecke A, Hersmus N, Geelen V, D'Hollander I, Thijs V, Van Den Bosch L, Carmeliet P, Robberecht W. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Human Molecular Genetics. 2007;16:2359–2365. doi: 10.1093/hmg/ddm193.
    1. Lim PJ, Danner R, Liang J, Doong H, Harman C, Srinivasan D, Rothenberg C, Wang H, Ye Y, Fang S, Monteiro MJ. Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. The Journal of Cell Biology. 2009;187:201–217. doi: 10.1083/jcb.200903024.
    1. Mah AL, Perry G, Smith MA, Monteiro MJ. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. The Journal of Cell Biology. 2000;151:847–862. doi: 10.1083/jcb.151.4.847.
    1. Maro GS, Klassen MP, Shen K. A beta-catenin-dependent wnt pathway mediates anteroposterior axon guidance in C. elegans motor neurons. PLoS One. 2009;4:e4690. doi: 10.1371/journal.pone.0004690.
    1. Marín I. The ubiquilin gene family: evolutionary patterns and functional insights. BMC Evolutionary Biology. 2014;14:63. doi: 10.1186/1471-2148-14-63.
    1. Miller N, Feng Z, Edens BM, Yang B, Shi H, Sze CC, Hong BT, Su SC, Cantu JA, Topczewski J, Crawford TO, Ko CP, Sumner CJ, Ma L, Ma YC. Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy. Journal of Neuroscience. 2015;35:6038–6050. doi: 10.1523/JNEUROSCI.3716-14.2015.
    1. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 Colon cancer cells. Biochemical and Biophysical Research Communications. 2005;328:227–234. doi: 10.1016/j.bbrc.2004.12.151.
    1. Ramesh T, Lyon AN, Pineda RH, Wang C, Janssen PM, Canan BD, Burghes AH, Beattie CE. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Disease Models & Mechanisms. 2010;3:652–662. doi: 10.1242/dmm.005538.
    1. Rezania K, Roos RP. Spinal cord: motor neuron diseases. Neurologic Clinics. 2013;31:219–239. doi: 10.1016/j.ncl.2012.09.014.
    1. Salinas PC, Zou Y. Wnt signaling in neural circuit assembly. Annual Review of Neuroscience. 2008;31:339–358. doi: 10.1146/annurev.neuro.31.060407.125649.
    1. Votin V, Nelson WJ, Barth AI. Neurite outgrowth involves adenomatous polyposis coli protein and beta-catenin. Journal of Cell Science. 2005;118:5699–5708. doi: 10.1242/jcs.02679.
    1. Wang L, Popko B, Roos RP. The unfolded protein response in familial amyotrophic lateral sclerosis. Human Molecular Genetics. 2011;20:1008–1015. doi: 10.1093/hmg/ddq546.
    1. Wishart TM, Mutsaers CA, Riessland M, Reimer MM, Hunter G, Hannam ML, Eaton SL, Fuller HR, Roche SL, Somers E, Morse R, Young PJ, Lamont DJ, Hammerschmidt M, Joshi A, Hohenstein P, Morris GE, Parson SH, Skehel PA, Becker T, Robinson IM, Becker CG, Wirth B, Gillingwater TH. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. Journal of Clinical Investigation. 2014;124:1821–1834. doi: 10.1172/JCI71318.
    1. Wu H, Lu Y, Barik A, Joseph A, Taketo MM, Xiong WC, Mei L. β-Catenin gain of function in muscles impairs neuromuscular junction formation. Development. 2012;139:2392–2404. doi: 10.1242/dev.080705.
    1. Wu Q, Liu M, Huang C, Liu X, Huang B, Li N, Zhou H, Xia XG. Pathogenic Ubqln2 gains toxic properties to induce neuron death. Acta Neuropathologica. 2015;129:417–428. doi: 10.1007/s00401-014-1367-y.

Source: PubMed

3
Abonnieren